Charles River Laboratories, a provider of drug discovery and development services, completed the acquisition of SAMDI Tech, a provider of high-quality, label-free high-throughput screening solutions for drug discovery research, for $50m. “The acquisition of SAMDI Tech’s cutting-edge, high-throughput screening technology further strengthens Charles River’s drug discovery capabilities and enhances our unique ability to serve as an integrated partner to support our clients’ early-stage research. SAMDI Tech’s platform combined with our premier, end-to-end drug discovery portfolio will generate better data and faster hit identification and is another step to accelerate our clients’ drug discovery efforts. With over a decade of industry experience and the successful, existing partnership, we believe the addition of SAMDI Tech will continue to generate new business opportunities and we are pleased to welcome them to the Charles River family,”James C. Foster, Charles River Laboratories Chairman, President and Chief Executive Officer.